Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate (HPTBI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03502967 |
Recruitment Status
:
Not yet recruiting
First Posted
: April 19, 2018
Last Update Posted
: April 25, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Traumatic Brain Injury | Drug: Hyperpolarized [1-13C] Pyruvate Drug: Hyperpolarized [2-13C] Pyruvate | Early Phase 1 |
Aim 1:
Investigators will quantify changes in [1-13C]lactate and H13CO3- labeling following a bolus injection of hyperpolarized [1-13C]pyruvate during the time window of secondary injury to assess upregulated glycolysis. Due to heterogeneous presence and severity of damage by TBI, defining the injured brain region can be difficult. Therefore, the metabolite ratio maps ([product]/[pyruvate]) of TBI patients (n = 5) will be compared with those of healthy-controls (n = 3).
Hyperpolarized [2-13C]pyruvate will be examined in a separate group of TBI cohorts (n = 5) and healthy controls (n = 3), and [5-13C]glutamate, [1-13C]acetyl-carnitine, [1-13C]acetoacetate, and [1-13C]citrate from [2-13C]pyruvate will be quantified for assessing the altered mitochondrial metabolism. Imaging procedure with [2-13C]pyruvate is the same as the imaging with hyperpolarized [1-13C]pyruvate.
For both [1-13C]pyruvate and [2-13C]pyruvate studies, each subject will be imaged twice with a 45min interval for confirming the reproducibility of the methods and/or averaging to enhance the signal-to-noise ratios of 13C-metabolite maps.
Aim 2:
After the feasibility study (aim1) is completed, an intra-subject comparison study of [1-13C]pyruvate and [2-13C]pyruvate will be performed. Similar to the aim1, patients with post-TBI neurological disorders having normal or near-normal CT results (n = 6 patients) as well as normal brains of age/gender-matching healthy volunteers (n = 3) will be recruited. Each patient will be imaged twice (one with [1-13C]pyruvate and one with [2-13C]pyruvate with a 45min interval). PDH activity and the TCA cycling will be assessed from measured H13CO3- from hyperpolarized [1-13C]pyruvate and [5-13C]glutamate from [2-13C]pyruvate, respectively. The comparison of [1-13C]pyruvate and [2-13C]pyruvate will identify the detailed information of how pyruvate (and converted acetyl-CoA) is utilized in the mitochondria, and assess the utility and necessity of imaging hyperpolarized [2-13C]pyruvate in TBI, providing critical data for future grant applications and larger clinical trials.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 16 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | TBI patients and healthy control subjects |
Masking: | None (Open Label) |
Primary Purpose: | Basic Science |
Official Title: | Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate |
Estimated Study Start Date : | May 1, 2018 |
Estimated Primary Completion Date : | October 31, 2019 |
Estimated Study Completion Date : | October 31, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Hyperpolarized [1-13C] Pyruvate
Injection with hyperpolarized [1-13C] Pyruvate during MRI.
|
Drug: Hyperpolarized [1-13C] Pyruvate
Bolus injection of study drug
Other Name: HP Pyruvate Injection
|
Experimental: Hyperpolarized [2-13C] Pyruvate
Injection with hyperpolarized [2-13C] Pyruvate during MRI.
|
Drug: Hyperpolarized [2-13C] Pyruvate
Bolus injection of study drug
Other Name: HP Pyruvate Injection
|
- [1-13C]lactate-to-H13CO3- ratio from [1-13C]pyruvate or [2-13C]lactate-to-[5-13C]glutamate ratio from [2-13C]pyruvate [ Time Frame: One visit of three hours: 2 bolus injections during MRI with 45 minute rest period between the two ]Product ratio maps of lactate from pyruvate in the brain of TBI patients as compared to those of healthy controls.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
TBI Patients
- Injury occurred within 10 days
- Documented and verified TBI by Glascow coma scal 10-15 and/or Loss of Consciousness >10 minutes.
- Head Computed Tomography at admission.
ALL Subjects:
- 18 through 60 years of age.
- Ability to understand the the willingness to sign a writteninformed consent.
- All races and ethnicities will be included; subjects must be able to read and speak either the English or Spanish language.
Exclusion Criteria:
- Non-traumatic structural brain abnormality identified on head CT.
- Metallic foreign bodies on the scalp or cranium which may interfere with MRI acquisitions.
- Penetrating TBI.
- Significant anatomic distortion of the brain identified on CT images, such as large hematomas, herniation, intraventricular hemorrhage, extensive subarachnoid hemorrhage, hydrocephalus.
- Significant polytrauma that would interfere with follow-up and outcome assessment.
- Patients on psychiatric hold.
- Major debilitating mental health disorders including, but not limited to schizophrenia and bipolar disorder that would limit compliance with study requirements.
- Major debilitating neurological disease including, but not limited to, stroke, CVA, dementia and tumor that would limit compliance with study requirements.
- Under influence of illicit drugs which are known to alter brain physiology/metabolism including, but not limited to cocaine, lysergic acid diethylamide (LSD), and marijuana at the time of MRI/MRSI scanning.
- Any contraindication per MRI Screening Form including
- Implants contraindicated at 3T, pacemakers
- Implantable Cardioverter Defibrillator (ICD)
- Claustrophobia
- Prisoners or patients in custody.
- Medically unstable including
- Heart failure
- Severe left ventricular outflow tract (LVOT) obstruction
- Unstable angina
- Pregnancy
- Lactating
- Subjects who are receiving any other investigational agents.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03502967
Contact: Jeannie D Baxter, RN | 214-645-2726 | jeannie.baxter@utsouthwestern.edu | |
Contact: Lucy H Christie, BSN, RN | 214-645-2215 | lucy.christie@utsouthwestern.edu |
Responsible Party: | Jae Mo Park, Principal Investigator, University of Texas Southwestern Medical Center |
ClinicalTrials.gov Identifier: | NCT03502967 History of Changes |
Other Study ID Numbers: |
STU 072017-009 |
First Posted: | April 19, 2018 Key Record Dates |
Last Update Posted: | April 25, 2018 |
Last Verified: | April 2018 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | Yes | |
Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Jae Mo Park, University of Texas Southwestern Medical Center:
Traumatic Brain Injury TBI |
Additional relevant MeSH terms:
Wounds and Injuries Brain Injuries Brain Injuries, Traumatic Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Craniocerebral Trauma Trauma, Nervous System |